Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Auclin

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|June 6, 2022
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung CancerMariona Riudavets, Virginie Lamberts, Damien Vasseur, et al.
Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.
Clinical Genitourinary Cancer|February 7, 2026
Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell CarcinomaAlia Harba, Fabien Moinard-Butot, Edouard Auclin, et al.
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
ERJ Open Research|October 29, 2024
Persistent disabilities 28 months after COVID-19 hospitalisation, a prospective cohort studyBertrand Renaud, Richard Chocron, Guillaume Reverdito, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European CohortJulien Taïeb, Lina Sayah, Kathrin Heinrich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|June 6, 2022
Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung CancerMariona Riudavets, Virginie Lamberts, Damien Vasseur, et al.
Journal for Immunotherapy of Cancer|June 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLCMatthieu Roulleaux-Dugage, Andrey Yurchenko, Sergey Nikolaev, et al.
Clinical Genitourinary Cancer|February 7, 2026
Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell CarcinomaAlia Harba, Fabien Moinard-Butot, Edouard Auclin, et al.
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
ERJ Open Research|October 29, 2024
Persistent disabilities 28 months after COVID-19 hospitalisation, a prospective cohort studyBertrand Renaud, Richard Chocron, Guillaume Reverdito, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European CohortJulien Taïeb, Lina Sayah, Kathrin Heinrich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.
Pageof 9